1. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients
- Author
-
Philip S. Rudland, Helen Innes, Angela Platt-Higgins, Roger Barraclough, D R Sibson, D Liu, P A O'Neill, S de Silva Rudland, and Michael P.A. Davies
- Subjects
Adult ,Cancer Research ,Pathology ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,ERα-positive breast cancer ,AGR2 ,Breast Neoplasms ,Polymerase Chain Reaction ,Gastroenterology ,Metastasis ,Cohort Studies ,Mucoproteins ,patient survival ,Breast cancer ,Internal medicine ,Carcinoma ,medicine ,Humans ,Neoplasm Metastasis ,Molecular Diagnostics ,Aged ,Retrospective Studies ,Aged, 80 and over ,Immunoassay ,Oncogene Proteins ,business.industry ,Hazard ratio ,Proteins ,Middle Aged ,Prognosis ,medicine.disease ,Immunohistochemistry ,Survival Analysis ,Exact test ,Receptors, Estrogen ,Oncology ,Chemotherapy, Adjuvant ,Hormonal therapy ,Female ,business ,AGR2 immunocytochemistry - Abstract
The anterior gradient protein-2 (AGR2) is inducible by oestrogen and itself can induce metastasis in a rat model for breast cancer. Here, a rabbit antibody to recombinant human AGR2 was used to assess its prognostic significance in a retrospective cohort of 351 breast cancer patients treated by adjuvant hormonal therapy. The antibody stains 66% of breast carcinomas to varying degrees. The percentage of positive carcinoma cells in tumours directly correlates with the level of AGR2 mRNA (Spearman's rank correlation, P = 0.0007) and protein (linear regression analysis r2 = 0.95, P = 0.0002). There is a significant association of staining of carcinomas for AGR2 with oestrogen receptor alpha (ERalpha) staining and with low histological grade (both Fisher's Exact test P0.0001). In the ERalpha-positive cases, but not the ERalpha-negative cases, when subdivided into the separate staining classes for AGR2, there is a significantly progressive decrease in patient survival with increased staining (log rank test, P = 0.006). The significant association of staining for AGR2 with patient death over a 10-year period (log rank test P = 0.007, hazard ratio = 3) only becomes significant at 6 years of follow-up. This may be due to the cessation of adjuvant hormonal therapy at an earlier time, resulting in adverse re-expression of the metastasis-inducing protein AGR2.
- Published
- 2006